+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oral anticoagulants in frail patients with atrial fibrillation: moving in the uncertainty of daily clinical practice



Oral anticoagulants in frail patients with atrial fibrillation: moving in the uncertainty of daily clinical practice



Revista Espanola de Geriatria y Gerontologia 53(6): 311-313




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065868639

Download citation: RISBibTeXText

PMID: 30318135

DOI: 10.1016/j.regg.2018.07.007


Related references

Experience in daily clinical practice of ambulatory cardioversion of atrial fibrillation treated with new oral anticoagulants. Revista Espanola de Cardiologia 67(11): 960-961, 2014

Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). American Journal of Cardiology 119(10): 1590-1595, 2017

Efficacy and safety of oral anticoagulants in frail elderly patients with atrial fibrillation: an unsolved problem. Giornale Italiano di Cardiologia 18(3): 180-187, 2017

Frequency and Determinants of Adherence to Oral Anticoagulants in Stroke Patients with Atrial Fibrillation in Clinical Practice. European Neurology 76(3-4): 187-193, 2016

Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. Journal of Interventional Cardiac Electrophysiology 40(3): 261-268, 2014

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. British Journal of Clinical Pharmacology 85(2): 422-431, 2019

Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis 23(7): 711-724, 2017

As cardiologists how much do we take into account the guideline recommendations while prescribing oral anticoagulants to patients with atrial fibrillation our clinical practice? A striking result!. Anadolu Kardiyoloji Dergisi 13(7): 726-727, 2013

Use of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review. Seminars in Thrombosis and Hemostasis 44(4): 370-376, 2018

Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal Supplements 18(Suppl D): D1, 2016

Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients. Current Medical Research and Opinion 35(4): 653-660, 2019

Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience. Seminars in Thrombosis and Hemostasis 44(4): 364-369, 2018

From warfarin to new oral anticoagulants in clinical practice. What is the future of anticoagulant therapy in atrial fibrillation?. Monaldi Archives for Chest Disease 80(2): 55-56, 2013

Oral anticoagulation in patients aged 75 years or older with chronic non-valvar atrial fibrillation: effectiveness and safety in daily clinical practice. Heart 91(9): 1225-1226, 2005

Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs and Aging 27(1): 39-50, 2010